Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1625063

Case report:Genomic Insights and Personalized Treatment in Dual Primary Esophageal Squamous Cell Carcinoma and Gastric Adenocarcinoma

Provisionally accepted
Chuanwang  MiaoChuanwang Miao1Yaning  GuoYaning Guo1Huili  YangHuili Yang2Zhu  ShanZhu Shan3Yuanji  ChenYuanji Chen1Wei  ZhaoWei Zhao1*Xudong  HuXudong Hu1*
  • 1Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
  • 2Binzhou Central Hospital, Binzhou Central Hospital Affiliated to Binzhou Medical University, Binzhou, China
  • 3Shandong Provincial ENT Hospital, Shandong University, Jinan, China

The final, formatted version of the article will be published soon.

Dual primary malignancies in the upper gastrointestinal tract are rare and pose diagnostic and therapeutic challenges. This study reports a case of synchronous esophageal squamous cell carcinoma (ESCC) and gastric adenocarcinoma (GAC), highlighting the role of genetic profiling in personalized treatment. A 78-year-old female patient was diagnosed with stage IIB ESCC and stage IIIA GAC. Due to surgical ineligibility, she received chemoradiotherapy and immunotherapy. Next-generation sequencing (NGS) was performed to identify potential genetic drivers. Genetic analysis revealed common chromosomal amplifications on 19p and 21q but no shared driver mutations, suggesting independent tumor origins. ESCC exhibited amplifications of MCL1, RECQL4, NKX2-1, PARP10, RSPO1, MUCL, and WTIP, while GAC showed deletions of APC and PRKG1, along with amplifications of ARRDC1 and NRARP. The patient achieved stable disease without recurrence following chemoradiotherapy and Sintilimab immunotherapy. This case underscores the role of genetic alterations in dual primary cancers and demonstrates the feasibility of precision treatment.

Keywords: Dual primary cancer, esophageal squamous cell carcinoma, Gastric adenocarcinoma, nextgeneration sequencing, Chromosomal alterations Abstract:

Received: 14 May 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Miao, Guo, Yang, Shan, Chen, Zhao and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Wei Zhao, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Xudong Hu, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.